^
    Back
    Association details:
    Biomarker:DDR
    Cancer:Prostate Cancer
    Drug:abiraterone acetate (CYP17A1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    ESMO 2019
    Title:

    EVALUATION OF MARKERS ASSOCIATED WITH EFFICACY OF ABIRATERONE ACETATE PLUS PREDNISONE (AAP) IN PATIENTS (PTS) WITH CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC) FROM THE LATITUDE STUDY

    Published date:
    09/30/2019
    Excerpt:
    In the AAP arm, shorter PFS was observed for DRD+ vs DRD– cohort (median 21.01 vs 24.14 mo; HR: 3.9; 95% CI: 1.1-12.1; p = 0.03)…The DRD+ cohort appears to show poorer rPFS outcome in AAP treated men.
    Trial ID:
    LATITUDE